| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
There are at least 2 subsets of colon macrophages that differ in the expression level of CD169. Selective depletion of CD169 macrophages suppresses DSS-induced colitis in mice. In this study, we revealed that CD169 macrophages produce CCL8 in response to mucosal injury, and that CCL8 recruits inflammatory monocytes to the intestine that furhter aggravate colitis. Administration of anti-CCL8 ameliorates DSS-induced colitis, demonstrating its potential as a novel drug for the treatment of human inflammatory bowel diseases.
|
